IV SIMPOSIO CIENTÍFICO SOGUG

Transcripción

1 IV SIMPOSIO CIENTÍFICO SOGUG 4th SCIENTIFIC MEETING SOGUG Comité Científico Scientific Committee Dr. Daniel Castellano Dr. Ignacio Durán Dr. Miguel Ángel Climent Dra. Aránzazu González del Alba Dr. Javier Cassinello Dra. María José Méndez -Vidal Dr. Luis León Dra. Marta López-Brea Dr. Juan Francisco Rodríguez-Moreno Madrid, 20 al 22 Noviembre 2013 / Madrid, 20th to 22nd November 2013

2 Miércoles, 20 noviembre / Wednesday, 20 th November 18:00-19:30 ENCUENTROS CON EL EXPERTO / MEET WITH THE EXPERT GRUPO 1 / GROUP 1 Meet with the expert - Principios básicos de bioestadística en oncología / Meet with the expert - Basic principles of biostatistics in oncology Alejandro Pedromingo, Technical Director, Bio-estadística.com, Madrid Auspiciado por GSK Plazas limitadas GRUPO 2 / GROUP 2 Meet with the expert - Próstata / Meet with the expert- Prostate Dr. Eric Small, Urologic Cancer Service and Urologic Oncology Research, UCSF Medical Center, San Francisco, USA Auspiciado por JANSSEN Plazas limitadas *Actividades en pequeños grupos, para asistir es necesario estar inscrito en el Simposio y solicitar previa asistencia a la Secretaría Técnica. Activities in small groups. To access these sessions it is necessary to be registered in the Symposium and have previously requested attendance to the Technical Secretariat.

3 Jueves, 21 noviembre / Thursday, 21 st November 08:45-09:45 SESIÓN INTERACTIVA JÓVENES INVESTIGADORES (I): OTRAS OPCIONES PROFESIONALES / INTERACTIVE SESSION YOUNG INVESTIGATORS (I): OTHER PROFESSIONAL OPTIONS Oportunidades de trabajo en el extranjero / Professional opportunities abroad canadá / Canada Dr. Ignacio Durán, Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío, Sevilla eeuu / USA Dr. Charles Ryan, Urologic Oncology Practice, UCSF Medical Center, San Francisco, USA La industria farmacéutica / The pharmaceutical industry Dr. Enrique Grande, Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid Debate abierto / Open debate 09:45-10:00 INAUGURACIÓN / OPENING REMARKS Dra. Isabel Oriol, Presidenta AECC Dr. Daniel Castellano, Presidente SOGUG 10:00-11:30 RETOS EN EL CÁNCER DE VEJIGA AVANZADO CHALLENGES IN ADVANCED BLADDER CANCER Moderadores / Chairpersons Dr. José A. Arranz, Servicio de Oncología Médica, Hospital Universitario Gregorio Marañón, Madrid 10:00-10:20 Cáncer de vejiga avanzado: factores pronósticos y predictivos Advanced bladder cancer: prognostic and predictive factors Dr. Jonathan Rosenberg, Associate Physician and Section Head, Memorial Sloan-Kettering Cancer Center, New York, USA

4 Jueves, 21 noviembre / Thursday, 21 st November 10:20-10:40 Progresión después de quimioterapia basada en cisplatin: opciones en la actualidad y desarrollo futuro / Progression after cisplatin-based chemotherapy: current options and future development Dr. Javier Puente, Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Madrid 10:40-11:00 Discusión / Discussion 11:00-11:30 SESIÓN PLENARIA / PLENARY SESSION Presenta / Presents Dra. Begoña Mellado, Servicio de Oncología Médica, Hospital Clínic, Barcelona Tratamiento individualizado en cáncer de vejiga / Individualizing treatment in bladder cancer Dr. Jonathan Rosenberg, Associate Physician and Section Head, Memorial Sloan-Kettering Cancer Center, New York, USA 11:30-12:00 Descanso café / Coffee break 12:00-13:00 RETOS EN EL CÁNCER DE PRÓSTATA LOCALIZADO CHALLENGES IN LOCALIZED PROSTATE CANCER Moderadores/ Chairpersons Dr. Francisco Gómez-Veiga, Servicio de Urología, Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña Dr. Alfredo Ramos, Servicio de Oncología Radioterápica, Hospital Universitario Ramón y Cajal, Madrid 12:00-12:20 Observación en cáncer de próstata localizado, el desafío de la patología y biomarcadores / Surveillance in localized prostate cancer, the pathology and biomarker challenge Dr. José Rubio, Servicio de Urología, Instituto Valenciano de Oncología (IVO), Valencia

5 Jueves, 21 noviembre / Thursday, 21 st November 12:20-12:40 Se convertirá la terapia focal en un standard de tratamiento en el cáncer de próstata de bajo riesgo? / Will focal therapy become the standard of care in low risk prostate cancer? Dr. Hashim Ahmed, Division of Surgery and Interventional Science, University College, London, UK 12:40-13:00 Discusión / Discussion 13:00-13:30 SESIÓN PLENARIA / PLENARY SESSION Presenta / Presents Dr. Javier Cassinello, Servicio de Oncología Médica, Hospital General Universitario, Guadalajara Tratamiento del cáncer de próstata localmente avanzado: cuánto y por cuánto tiempo? / Treatment of locally advanced prostate cancer: how much and for how long Dr. Joan Carles, Servicio de Oncología Médica, Hospital General Universitari Vall d Hebron, Barcelona 13:30-15:00 Almuerzo / Lunch 13:30-15:00 WORKSHOPS SIMULTÁNEOS CON ALMUERZO JANSSEN El presente del cáncer de próstata resistente a castración PFIZER Trasladando la evidencia y la experiencia al control integral del cáncer renal 15:30-17:20 INVESTIGACIÓN TRASLACIONAL EN EL CÁNCER DE PRÓSTATA TRASLATIONAL RESEARCH IN PROSTATE CANCER Moderadores / Chairpersons Dr. David Olmos, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid Dr. Enrique González-Billalabeitia, Servicio de Oncología Médica, Hospital General Universitario Morales Meseguer, Murcia

6 Jueves, 21 noviembre / Thursday, 21 st November 15:30-15:50 El papel de BRCA1 y BRC2 en cáncer de próstata / The role of BRCA1 and BRC2 in prostate cancer Dra. Elena Castro, Unidad de Investigación Clínica de Cáncer de Próstata y Tumores Genitourinarios, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid 15:50-16:10 La inhibición de PARP como nueva estrategia contra el cáncer de próstata / PARP inhibition as a new strategy to target prostate cancer Dr. Karen E. Knudsen, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA 16:10-16:30 Vulnerabilidad del cáncer de próstata asociado a la pérdida de PTEN / PTEN-loss prostate cancer vulnerabilities Dr. Enrique González-Billalabeitia, Servicio de Oncología Médica, Hospital General Universitario Morales Meseguer, Murcia 16:30-17:00 SESIÓN PLENARIA / PLENARY SESSION Nuevas estrategias en la oncología clínica traslacional en CRPC New strategies in clinical translational oncology in CRPC Dr. Johann S. De Bono, Department of Medical Oncology, The Royal Marsden, London, UK 17:00-17:20 Discusión / Discussion 17:20-17:35 Balance de la actividad científica del grupo SOGUG Balance of scientific activity of SOGUG group Dra. Nuria Lainez, Vicepresidenta SOGUG 18:00-19:00 Asamblea General SOGUG / SOGUG General Assembly

7 Viernes, 22 noviembre / Friday, 22 nd November 08:30-09:25 RETOS EN CÁNCER RENAL. SITUACIONES ESPECIALES CHALLENGES IN RENAL CANCER. SPECIAL SITUATIONS Moderadores / Chairpersons Dr. Javier Angulo, Servicio de Urología, Hospital Universitario de Getafe, Madrid Dr. Guillermo de Velasco, Servicio de Oncología Médica, Hospital Universitario 12 de Octubre, Madrid 08:30-08:50 La vía de mtor: la base para el tratamiento de ciertas histologías mtor pathway: the rationale to target certain histologies Dr. Ignacio Durán, Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío, Sevilla 08:50-09:10 Angiomiolipomas: un nuevo tratamiento para enfermedades raras / Angiomiolipomas: a new treatment for a rare disease Dra. Roser Torra, Servicio de Nefrología, Fundació Puigvert, Barcelona 09:10-09:25 Discusión / Discussion 09:30-11:30 CÁNCER DE PRÓSTATA: RETOS EN ENFERMEDAD AVANZADA PROSTATE CANCER: CHALLENGES IN ADVANCED DISEASE Moderadores / Chairpersons Dr. Miguel Ángel Climent, Servicio de Oncología Médica, Instituto Valenciano de Oncología (IVO), Valencia Dr. Francisco Zambrana, Servicio de Oncología Médica, Hospital Universitario Infanta Sofía, Madrid 09:30-09:50 Tratando la enfermedad ósea en el cáncer de próstata: opciones de tratamiento en la actualidad / Targeting bone disease in prostate cancer: current treatment options Dr. Karim Fizazi, Department of Medicine, Institute Gustave-Roussy, Villejuif, France 09:50-10:10 Inhibidor CYP17: cuándo y a quién? / CYP17 inhibition: when and to whom Dr. Eric Small, Urologic Cancer Service and Urologic Oncology Research, UCSF Medical Center, San Francisco, USA

8 Viernes, 22 noviembre / Friday, 22 nd November 10:10-10:30 El receptor de andrógenos como objetivo en el cáncer de próstata avanzado / The androgen receptor as a target in advanced prostate cáncer Dr. Eleni Efstathiou, GU Medical Oncology Associate Professor, MD Anderson Cancer Center, Houston, USA 10:30-10:50 Estrategias para superar la resistencia de andrógenos Strategies to overcome androgen resistance Dr. Charles Ryan, Urologic Oncology Practice, UCSF Medical Center, San Francisco, USA 10:50-11:10 El impacto de la quimioterapia en pacientes con CPRC The impact of chemotherapy in CRPC patients Dr. Stephane Oudard, Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France 11:10-11:30 Discusión / Discussion 11:30-12:00 Descanso café / Coffee break 12:00-12:45 CONFERENCIA ESPECIAL / SPECIAL LECTURE Presenta / Presents Dr. Pablo Maroto, Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona 12:00-12:30 Altas dosis de quimioterapia en tumores de células germinales: cuándo y a quién? / High dose chemotherapy in germ cell tumors: when and to whom Dr. Karim Fizazi, Department of Medicine, Institute Gustave-Roussy, Villejuif, France 12:30-12:45 Discusión / Discussion

9 Viernes, 22 noviembre / Friday, 22 nd November 12:50-14:00 RETOS EN CÁNCER RENAL / KIDNEY CANCER. CHALLENGES Moderadores / Chairpersons Dra. Marta López-Brea, Servicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander Dr. Xavier García Del Muro, Servicio de Oncología Médica, Institut Català d Oncologia-Hospital Duran i Reynals 12:50-13:10 Terapia neoadyuvante y adyuvante en RCC localizado: hay papel para los TKIs?/ Neo adjuvant and adjuvant therapy in localized RCC: is there a role for TKIs? Dr. Tom Powles, Clinical Professor of Genitourinary Oncology (HCC), Barts Cancer Institute, London, UK 13:10-13:30 Tratamiento individualizado en RCC avanzado: cómo incorporar todas las opciones disponibles? / Individualized treatment in advanced RCC: how to incorporate all the available options Dr. Camilo Porta, Department of Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy 13:30-13:50 Hay algo más allá de la inhibición de TKIs y mtor?: nuevas estrategias de tratamiento en RCC avanzado / Is there anything beyond TKIs and mtor inhibition: new treatment strategies in advanced RCC Dr. Jesús García-Donas, Servicio de Oncología Médica, Hospital de Madrid Norte Sanchinarro-CIOCC, Madrid 13:50-14:00 Discusión / Discussion

10 Viernes, 22 noviembre / Friday, 22 nd November 14:00-15:30 WORKSHOPS SIMULTÁNEOS CON ALMUERZO BAYER - Supervivencia global y calidad de vida en pacientes con cáncer de próstata resistente a la castración y metástasis óseas sintomáticas. Revisión de casos clínicos y perfiles de pacientes NOVARTIS - Escenarios clínicos en la consulta diaria de pacientes con cáncer renal 14:00-15:30 GRUPO 3 / GROUP 3 Meet with the expert-vejiga / Meet with the expert-bladder Dr. Joaquim Bellmunt, Dana-Farber/ Brigham and Women s Cancer Center, Harvard University, Boston, USA Auspiciado por PIERRE FABRE Plazas limitadas para asistir es necesario estar inscrito en el Simposio y solicitar previa asistencia a la Secretaría Técnica / Limited places- to access this session it is necessary to be registered in the Symposium and have previously requested attendance to the Technical Secretariat 16:00-17:15 SESIÓN INTERACTIVA JÓVENES INVESTIGADORES (II): CONCURSO DE CASOS CLÍNICOS-IMÁGENES MÉDICAS INTERACTIVE SESSION YOUNG INVESTIGATORS (II): CLINICAL VIGNETES-MEDICAL IMAGES CONTEST Moderadores / Chairpersons Dra. María José Méndez -Vidal, Servicio de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba Dra. Aránzazu González Del Alba, Servicio de Oncología Médica, Hospital Universitari Son Espases, Palma de Mallorca Casos clínicos / Clinical vignettes Discusión / Discussion Dr. Juan Francisco Rodríguez-Moreno, Servicio de Oncología Médica, Hospital de Madrid Norte Sanchinarro-CIOCC, Madrid

11 Viernes, 22 noviembre / Friday, 22 nd November Imágenes médicas / Medical images Discusión / Discussion Dr. Luis León, Servicio de Oncología Médica, Complejo Hospitalario Universitario de Santiago (CHUS), A Coruña Entrega de premios / Awards ceremony Dra. Nuria Lainez, Vicepresidenta SOGUG 17:15 Clausura del Simposio / Closing remarks Dr. Daniel Castellano, Presidente SOGUG

12 Dr. Hashim Ahmed Division of Surgery and Interventional Science, University College, London, UK MRC Clinician Scientist and Clinical Lecturer in Urology. Hashim qualified from the University of Oxford where he attended St Peters College and Linacre College. Whilst he was a student he was awarded the William Osler Prize in Medicine. He then held house office posts in Queen Elizabeth Hospital, Birmingham and University Hospitals Manchester before returning to Oxford for a Anatomy Prosector post. Hashim then held senior house jobs in surgery on the Royal Free Hospital, London rotation followed by specialist registrar posts at West Middlesex Hospital, Charing Cross Hospital/Imperial College, University College Hospital and Watford General Hospital as part of the Imperial College Urology Rotation. He was a Pelican Cancer Foundation Research Fellow followed by a MRC Clinician Research Training fellowship at University College London at which time a number of imaging and focal therapy trials were started. His research interests are in Health Technology Evaluation including multi-parametric MRI, Histoscanning, Tissue Type Imaging, as well as therapeutic interventions such as high intensity focused ultrasound, irreversible electroporation, and photodynamic therapy. He has completed three phase I/II clinical trials evaluating the role of focal therapy in prostate cancer and is lead PI and Co-PI in a number of multicentre trials including the UK NIHR-HTA funded study PROMIS study evaluating the role of multi-parametric MRI in men with a raised PSA using Template Prostate Mapping as the reference standard as well as INDEX, a multicentre focal therapy study using HIFU with 3 year follow-up. He currently holds a 1.2M MRC Clinician Scientist Fellowship for 5 years. Dr. Javier Angulo Servicio de Urología, Hospital Universitario de Getafe, Madrid Urologist. Doctorate Award in Universidad del País Vasco-Euskal Herriko Unibersitatea. ECFMG and EBU (UEEM) certified. Wayne State University Fellow, Harper Hospital (Detroit, Michigan). Jefe de Servicio de Urología in Hospital Universitario de Getafe (Madrid) and Profesor Titular, Universidad Europea de Madrid, Laureate International Universities. Director of Actas Urológicas Españolas, Oficial Journal of AEU and CAU. Master in Dirección Sanitaria y Gestión Clínica. Is author of 266 articles (186 of them in Science Citation Index) and 37 books. Total Impact Factor (SCI) 188,473. H-index (Web of Science) 17. Hobbies: Cultural Anthropology and ice age Art.

13 Dr. José A. Arranz Servicio de Oncología Médica, Hospital Universitario Gregorio Marañón, Madrid - Licenciado en Medicina y Cirugía (Universidad de Valladolid, 1985). - Especialista en Oncología Médica (Hospital General Universitario Gregorio Marañón, 1990). - Miembro del Comité de Expertos en Tumores Urológicos de la Consejería de Salud de la Comunidad Autónoma de Madrid (1993). - Diplomatura en Informática y Estadística (Universidad Autónoma de Barcelona, 1994). - Jefe de Sección del Sº de Oncología Médica del Hospital General Universitario Gregorio Marañón (desde 2007 hasta la actualidad), y responsable de la Unidad de Tumores Urológicos y Ginecológicos en dicho centro. Dr. Joan Carles Servicio de Oncología Médica, Hospital General Universitari Vall d Hebron, Barcelona El Dr. Joan Carles es licenciado en Medicina y Cirugía por la Universidad Autónoma de Barcelona (1987), obteniendo su doctorado en Completó su formación en la especialidad de Oncología Médica en el Hospital Universitario Germans Trias i Pujol de Badalona y en 1996 recibió el Certificado Europeo en Oncología Médica de Viena. En 1991 se incorporó a la Unidad de Oncología Médica del Hospital de Terrassa y desde abril 1992 hasta septiembre 2008 trabajó como médico oncólogo en el Hospital del Mar de Barcelona. En septiembre de 2008 se incorporó al Departamento de Oncología de Vall d Hebron como Jefe de la unidad de Genitourinario, sistema nervioso central, sarcoma y tumores de origen desconocido. El Dr. Joan Carles es co-fundador y vicepresidente de la Sociedad Española para el Tratamiento de Cáncer genitourinario (SOGUG), miembro de la Sociedad Española de Tumores de Cabeza y Cuello (CTT), así como miembro del Grupo Español de Investigación en Sarcoma ( GEIS). Es profesor de Medicina en la Universidad Autónoma de Barcelona desde 1995 y coordinador del programa de formación de Oncología Médica. El Dr. Carles ha sido autor de alrededor de más de 70 artículos y más de 100 presentaciones en congresos y capítulos de libros. Sus intereses de investigación son la oncología clínica genitourinaria, el sarcoma y principios de la investigación traslacional y clínica de los polimorfismos genéticos, así como la angiogénesis, como objetivos en la terapia del cáncer. También coordina los ensayos clínicos multicéntricos nacionales de los nuevos medicamentos en el tratamiento de la próstata, el riñón y el cáncer de vejiga. Además, el Dr. Carles es un miembro de la Sociedad Americana de Oncología Clínica (ASCO), miembro de la Sociedad Europea de Oncología Médica (ESMO) y miembro de la Asociación Española de Oncología Médica (SEOM). Ha actuado como consultor en calidad de asesor para la preparación y el desarrollo de las Directrices de Oncología para el gobierno de Catalunya (Oncoguies CatSalut).

14 Dr. Javier Cassinello Servicio de Oncología Médica, Hospital General Universitario, Guadalajara Especialista en Oncología Médica. Residencia (MIR) efectuada en en Hospital 12 de Octubre de Madrid en el Servicio de Oncología Médica. Título Europeo de Especialista en Oncología Médica de la ESMO (European Society of Medical Oncology ). Médico Adjunto de Oncología Médica en la Unidad de Oncología Médica del Hospital Miguel Servet de Zaragoza desde Febrero de 1992 hasta Diciembre de Médico Adjunto-Responsable de la Unidad de Oncología Médica del Hospital General Universitario de Guadalajara desde Diciembre de 1995 hasta la actualidad. Jefe de Sección desde Julio de 2005 Estancias científicas en el Hospital de Oulu (Finlandia) y en en el UTM Anderson Cancer Center, Houston (Texas) EE UU. 10 artículos en revistas internacionales, 15 artículos en revistas nacionales, 17 capítulos de libros, 60 comunicaciones a Congresos nacionales y extranjeros. Miembro de la Sociedad Española de Oncología Médica (SEOM), de la European Society of Medical Oncology (ESMO) y de la American Society of Clinical Oncology (ASCO) Áreas científicas de interés: Tumores Genitourinarios y Ginecológicos. Dr. Daniel Castellano Presidente SOGUG Dr Castellano is a Medical Oncologist of University Hospital 12 de Octubre (Madrid) with a special interest in the diagnosis and treatment of genitourinary tumors such as renal, bladder, prostate and testicular cancer. He currently Head of the GU Oncology Unit, Germ Cell Tumors Unit and Neuroendocrine Tumors Unit. His research is focused on the development of new drugs in GU tumors and Neuroendocrine tumors, and he is the Principal Investigator of more than 15 clinical trials (phase I, II and III trials). He has published more than 30 peer-review articles in relevant and recognized oncology journals. Dr Castellano is Chair of Spanish Oncology Genitourinary Group (SOGUG), member of executive committee of GETNE (Spanish Group of Neuroendocrine tumors), and member of a different International and National Scientific organizations.

15 Dra. Elena Castro Unidad de Investigación Clínica de Cáncer de Próstata y Tumores Genitourinarios, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid Elena Castro was born in Salamanca (Spain) in She received her MD from Universidad de Salamanca in 2003 and her PhD from the same university in Elena specialized in Medical Oncology at Hospital Uiversitario de Salmanca, obtaining her license to practice in After completing her residency training, she moved to London where she worked for four years as clinical research fellow in cancer genetics and prostate cancer at the Insitute of Cancer Research & The Royal Marsden Hospital. With Prof R Eeles as her mentor, Elena focussed her research in populations with high risk of prostate cancer and the clinical and molecular characterization of prostate cancer tumours that harbor BRCA mutations. Dr Castro moved back to Spain in January 2013 to the Prostate Cancer and GU tumours unit at the Spanish National Cancer Research Centre (CNIO) where she continues with her previous line of research. Dr. Johann S. De Bono Department of Medical Oncology, The Royal Marsden, London, UK Professor Johann de Bono was appointed as Senior Lecturer and Honorary Consultant in Medical Oncology at The Royal Marsden and The Institute of Cancer Research in He is now a Professor in Experimental Cancer Medicine at The Royal Marsden where he works in the clinical drug development of Phase I trials and has a particular interest in rationally designed molecular targeted therapies and prostate cancer.

16 Dr. Guillermo de Velasco Servicio de Oncología Médica, Hospital Universitario 12 de Octubre, Madrid Specialty training in Medical Oncology. University Hospital 12 de Octubre Clinical Fellowship: Genitourinary, Central Nervous System and Neuroendocrine tumors. University Hospital 12 de Octubre May 2013-Currently: Clinical Research Fellowship in Addenbrooke s Hospital (University of Cambridge). Research field: Metabolomic Profiling in kidney cancer. Dr. Ignacio Durán Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío, Sevilla El Dr. Ignacio Durán es coordinador de docencia y del programa de tumores genitourinarios del centro Integral Oncológico Clara Campal del Grupo Hospital de Madrid. Licenciado en Medicina y Cirugía por la Universidad de Salamanca y Doctor por la Universidad Complutense de Madrid. A lo largo de su carrera ha desarrollado estancias formativas en distintos centros investigadores nacionales e internacionales tales como la sede del CSIC de la Universidad de Salamanca, la Universidad Católica del Sacro Cuore de Roma (Italia), el Centre Hospitalier Universitaire» de Nantes (Francia) y el Memorial Sloan Kettering Cancer Center de Nueva York, (EE.UU). Tras su formación clínica en el Hospital Clínico Universitario de Son Dureta (Palma de Mallorca, Baleares, España), trabajó en el Servicio de Oncología Médica del Hospital Universitario Doce de Octubre (Madrid) y durante el trienio en los departamentos de Desarrollo de Nuevos Fármacos y de Tumores Genitourinarios del Princess Margaret Hospital de Toronto (Ontario, Canadá). Durante su estancia en Toronto completo un programa de Máster de docencia orientada a la medicina en la Universidad de Toronto (Ontario). Es autor de importantes trabajos en diferentes ámbitos de la oncología médica publicados en destacadas revistas científicas. A lo largo de su carrera ha recibido entre otros galardones, el ASCO Foundation Merit Award, el Novartis Young Canadian Investigator Award y el University Health Network Outstanding Research Presentation Award.

17 Dr. Eleni Efstathiou GU Medical Oncology Associate Professor, MD Anderson Cancer Center, Houston, USA EDUCATION. Degree-Granting Education National and Kapodistrian University of Athens School of Medicine, Athens, Greece, MD, 1995, Medicine National and Kapodistrian University of Athens School of Medicine, Athens, Greece, PhD, 2004, Medicine EDUCATION. Postgraduate Training Clinical Internship, Public Health System of Greece Rural Service, Athens, Greece, Clinical Residency/Fellowship, (Dept of Therapeutics-Medical Oncology unit) National and Kapodistrian University of Athens School of Medicine, Athens, Greece, (3 years Internal Medicine/ 6 months Hematology /3 years Medical Oncology) Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, CREDENTIALS. Board Certification Internal Medicine Athens, Greece 12/03 ECFMG, 2/2007 EXPERIENCE/SERVICE. Academic Appointments Fellow, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 Instructor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 06/2007 2/2008 Instructor, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, /2012 Assistant Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2008 4/2009 Adjunct Assistant Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2009 present Assistant Professor, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, 7/2012-present Associate Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 04/2013

18 Dr. Karim Fizazi Department of Medicine, Institute Gustave-Roussy, Villejuif, France HOSPITAL AND LABORATORY APPOINTMENTS Beginning September 2009: Full Professor, Institut Gustave Roussy, University of Paris, France Since June 2005: Appointed Head of the Department of Medicine, Institut Gustave Roussy (IGR), France. Since 2004: Chairman of the Genito-urinary Oncology Group, Institut Gustave Roussy (IGR), France. Since 2001: Assistant Professor in Medical Oncology, Department of Medicine, Institut Gustave Roussy (IGR), France : Visiting Assistant Professor, Genitourinary Medical Oncology Department, MD Anderson cancer Center, Houston, TX, USA : Assistant Professor in Medical Oncology, department of Medicine, Institut Gustave Roussy (IGR), France : Appointed Chef de clinique (Fellow) Medical oncology, IGR : Appointed Interne des hôpitaux de Paris (Residency): - Medical Oncology, Department of Pr Marty, Hôpital St Louis (1995) - Medical Oncology, Department of Pr Droz and Dr Le Chevalier, IGR (1995) - Medical Oncology, Department of Pr Pouillart, Institut Curie (1993) - Medical Oncology, Department of Pr Tursz, IGR (1993) - Radiotherapy, Department of Pr Cosset, Institut Curie (1992) - Medical Oncology, Department of Dr Ruffié, IGR (1992) - Cardiology, Department of Pr Leca, Hôpital Laënnec (1991) - Emergency, Department of Dr Duliouste, La Rochelle (1991) 1994: Diplôme d Etudes Appliquées : Postgraduate Diploma prior to PhD, Fundamental Bases of Oncogenesis, Pr Tursz Laboratory, IGR MEDICAL AND SCIENTIFIC QUALIFICATIONS 2003: Ph.D. (Molecular Oncology) 1997 : «Ancien Chef de Clinique» (Fellowship), Medical Oncology 1995 : MD (Medical Oncology) 1990: Concours de l Internat de Paris (Competitive Examination) ranked 45 / 3000 candidates, Internal Medicine. October 1984 to June 1990: Medical school, University of Poitiers, France.

19 Dr. Xavier García Del Muro Servicio de Oncología Médica, Institut Català d Oncologia-Hospital Duran i Reynals Is Medical Oncologist, Coordinator of the Unit of Genitourinary Tumors, Sarcoma and Melanoma of the Medical Oncology Department at the Institut Català d Oncologia Bellvitge in Barcelona. He is Assistant Professor of Clinical Oncology at the University of Barcelona. He is member of the SOGUG Directive Board and coordinator of the renal cell cancer committee and was Chairman of The Spanish Group for Research on Sarcomas for 5 years. He has published more than 80 papers on genitourinary cancer and sarcoma in international scientific journals. Dr. Jesús García-Donas Servicio de Oncología Médica, Hospital de Madrid Norte Sanchinarro-CIOCC, Madrid Jesus Garcia-Donas was born in Alcalá de Guadaira (Sevilla) in He received his MD from the Universidad Complutense de Madrid in Since 2012 Jesus leads the Gynecological, Genitourinary and Skin Tumors Unit at the Centro Integral Oncológico Clara Campal (Madrid). By September 2012 he became associated investigator within the Prostate Cancer and Genitourinary Tumors Unit in the Spanish National Cancer Research Center.

20 Dr. Francisco Gómez-Veiga Servicio de Urología, Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña I studied Medicine at the University of Santiago de Compostela (Spain), where I obtained my Degree in Medicine. During , I received my internship training in Urology at the A Coruña University Hospital, where I received my degree as a PhD. My main activities have been concentrating on Kidney transplant and Uro-Oncology. Now, I am the Head of the Uro-Oncology/Prostate Cancer Unit. I received training in different European and US hospitals on different techniques and aspects of kidney transplant and oncology. I have been coordinator and member of the steering committee in different clinical trials (CT) and I have wide experience in more than 30 of them. These studies are mainly focused on uro-oncology. Nowadays, I am the main investigator in 10 running CT, Phase II- III, on Prostate cancer; from local to castrate-resistant prostate cancer, bladder cancer, Kidney tumors and BPH. We are also running different lines on basic research of prostate and bladder cancer, Micro-rna and CTC. I am the co-author of more than 100 published national and international articles. I have collaborated in 30 published books related to kidney transplant and uro-oncology. I am a peer reviewer for the Urological Journals Actas Españolas de Urología, Archivos Españoles de Urología, Urology International, Canadian Urological Association Journal among others, besides I work as active member of the Scientific Committee of Spanish Guidelines for prostate cancer, Spanish Urological Association European Board Urology EBU sub-specialty and member in the Scientific Committee of European Urological Association, and as an international reviewer for the French National Cancer Institute. I received awards from the Spanish and European Urological Associations and Société Internationale d Urologie in recognition for outstanding publications and presentations. I am an active member of the Spanish Urological Association AEU, the European Urological Association EAU -EBU Sub-speciality and Scientific Committee, and the American Urological Association AUA. Dr. Enrique González-Billalabeitia Servicio de Oncología Médica, Hospital General Universitario Morales Meseguer, Murcia Enrique González-Billalabeitia obtained his medical degree at the University of Navarra in 1998; he became specialist in Medical Oncology at 12 de Octubre university hospital in 2003 and he got his PhD at the University Complutense of Madrid in He has been a post-doctoral fellow, between 2010 and 2012, in Pandolfi s lab at the department of genetics in BIDMC/Harvard Medical School focused on prostate cancer research and treatment, and he is currently the coordinator of urology tumors in the department of medical oncology at Morales Meseguer University Hospital in Murcia, Spain. His major focus of research is to better understand prostate cancer biology and to identify new therapies.

21 Dra. Aránzazu González Del Alba Servicio de Oncología Médica, Hospital Universitari Son Espases, Palma de Mallorca Dra. Aránzazu González del Alba Baamonde holds a Degree in Medicine and Surgery from Madrid Autonomous University (1993). She completed her training in Clinical Oncology in Son Dureta University Hospital (Palma de Mallorca, ) and holds a Master in Molecular Oncology: Molecular bases of Cancer. Molecular Pathology Program of the National Oncological Research Centre (CNIO), recognized by the European School of Oncology ( ). She is a staff physician of the Department of Clinical Oncology of Son Espases Universitary Hospital and since 2002 she has directed the Unit of Urological and Gynaecological tumours. Since 2009 she forms part of the Steering Committee of the Spanish Oncology Genitourinary Group (SOGUG), coordinating the Teaching Commission. Dr. Enrique Grande Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid Enrique Grande is the Director of Research for the Medical Oncology Service and leads the Genitourinary and Endocrine Tumors Unit at Ramón y Cajal University Hospital in Madrid, Spain. Dr Grande received his medical degree from the Autónoma University of Madrid in From , Dr Grande completed his Residency and Fellowship at the University Hospital Clinico San Carlos in Madrid, under the direction of Professor Diaz-Rubio. He later qualified as a PhD at the Alcalá University thanks to a Spanish National Ministry of Health grant for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors liver metabolism. Dr. Grande also holds a Master Degree in Molecular Biology of Cancer by the Spanish National Oncology Center (CNIO). Dr. Grande has published more than 70 manuscripts in peer review journals Dr. Grande is the editor of several books about Oncology. Dr Grande is currently the Chair of the Spanish Group for Research in Orphan and Infrequent Tumors (GETHI). His research focuses on advances in treatment of gastroenteropancreatic neuroendocrine tumours, renal cell carcinoma, bladder and prostate cancers, and thyroid malignancies.

22 Dr. Karen E. Knudsen Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA Dr. Karen E Knudsen is a Professor of Cancer Biology, Urology and Radiation Oncology and Vice Chair of Cancer Biology at Thomas Jefferson University. Dr. Knudsen also serves as the Deputy Director of Basic Science and the Hilary Koprowski Chair for the Kimmel Cancer Center. Dr. Knudsen s research interests focus on the mechanisms by which androgen governs prostate cancer growth, pathways that deregulate this process in disease progression, and the influence of both environmental and genetic factors on therapeutic response. Dr. Knudsen currently heads the Greater Philadelphia Prostate Cancer Working Group, which strives to facilitate collaborative research among the many talented basic, translational, and clinical researchers throughout the greater Delaware Valley, and increase awareness about the breadth of prostate cancer research in the area. Dra. Nuria Lainez Vicepresidenta SOGUG Investigational Site: Hospital de Navarra. Servicio de Oncología Médica. Education: MD, 1993 University of Zaragoza. Spain 1994, Medical Oncology Post Graduate Positions: Resident in Medical Oncology, , Hospital Universitario de Sant Joan. Reus. Tarragona. Spain Consultant in Medical Oncology, , Hospital Universitario de Sant Joan. Reus. Tarragona. Spain Consultant in Medical Oncology, , Instituto Catalán de Oncología. Hospitalet de Llobregat. Barcelona. Spain Consultant in Medical Oncology, , Hospital Universitario de Sant Joan. Reus. Tarragona. Spain Current Position: Consultant in Medical Oncology 2002 Hospital de Navarra. Servicio de Oncología Médica. Experience in Clinical Trials: Experience in 28 Phase II, III and IV clinical trials as principal investigator and co-investigator in tumors and sarcomas. Publications: 8 scientific papers in international/national peer-reviewed journals 1 national book chapter

23 Dr. Luis León Servicio de Oncología Médica, Complejo Hospitalario Universitario de Santiago (CHUS), A Coruña El Dr. León es un miembro activo del Spanish Oncology Genitourinary Group (SOGUG) y el Grupo Germinal. Ha publicado numerosos artículos y capítulos de libros y actualmente trabaja en el Servicio de Oncología Médica del Hospital Clínico Universitario de Santiago de Compostela. Presenta un interés especial en el uso de las Células Tumorales Circulantes como medio de actividad de nuevos fármacos, y también en los criterios de evaluación radiológica de respuesta. Dr. Pablo Maroto Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona Dr Maroto is a medical oncologist working in the Sant Pau Hospital of Barcelona, Spain since From his position, Dr Maroto has been actively working in the uro-oncology arena participating in more than 30 international clinical trials as principal investigator. He is member of different collaborative groups, among them the Spanish Oncology Genito-Urinary Group (SOGUG) where he has collaborated in the elaboration of Spanish Guidelines for the management of prostate, kidney and bladder cancer. Besides, he presently is the Chairman of the Germ Cell Cancer Group, the Spanish collaborative group for the treatment of Germ Cell cancer. Dra. Begoña Mellado Servicio de Oncología Médica, Hospital Clínic, Barcelona Begoña Mellado realizó sus estudios de Medicina en la Universidad de Barcelona y la especialidad de Oncología Médica en el Hospital Clinic de la misma ciudad. Completó su formación en biología celular y molecular en el Memorial Sloan Kettering de New York (USA), Obtuvo el grado de Doctor en Medicina por la Universidad de Barcelona en el año En la actualidad, es Consultor, del Servicio de Oncología Médica y Coordinadora Adjunta de la Unidad de Cáncer Urológico del Hospital Clinic de Barcelona.

24 Dra. María José Méndez-Vidal Servicio de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba Dr. Mendez-Vidal is Associate Professor at Cordoba University and an active member of the Spanish Oncology Genitourinary Group (SOGUG) and the Spanish Society of Medical Oncology. Dr. Mendez-Vidal received her M.D. degree from the Universidad of Malaga. She performed the Medical Oncology Residency at Clinical University Hospital in Cordoba Spain. She joined the staff at the Medical Oncology Service of University Hospital in Cordoba and she is the Responsible of the Uro-oncological Unit. Her research interests are in Clinical GU Oncology, with special attention to prostate and renal cancer. Dr. Stephane Oudard Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France Stéphane Oudard received his medical degree from Hôtel-Dieu Hospital, University of Paris. On completion of his residency in medical oncology, Prof. Oudard obtained his master of science from Lariboisière-Saint Louis University Hospital, Paris, and his doctorate from Institut Curie, Paris. He completed a 2-year fellowship in cancer research at Georgetown University, Washington, DC, USA, before returning to Paris. Prof. Oudard is the author of more than 170 scientific articles and 30 literature reviews published in various international journals. He also serves as a reviewer for several leading journals, including Journal of Clinical Oncology, Annals of Oncology, European Urology, and European Journal of Cancer. He is currently an active member of the French Cancer Society, the European Society for Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). As a clinical researcher, Prof. Oudard has served as a coordinator, investigator or co-investigator on several phase 1, 2 and 3 French, European, and international clinical trials. He has been highly involved in the development of cabazitaxel, sorafenib, sunitinib, and everolimus in uro-oncologic tumors. His research interests include prostate and kidney cancers, translational research, angiogenesis, inhibition of glycolysis, and drug resistance. He is the principal investigator of the Rising PSA phase 3 trial and the PREDICT trial.

25 Alejandro Pedromingo Technical Director, Bio-estadística.com, Madrid Professional present. Technical Director at Bio-estadistica.com ( Biometry Manager. Medical Department, GlaxoSmithKline, Tres Cantos, Madrid Head of Biostatistics. Medical Division, Glaxo / GlaxoWelcome Head of Statistics. R&D Dept., Bayer Registrations and Control/Manufacturing Specifications Analyst. R&D Dept., ERT Univ. Education & Studies Managerial Development Program (MDP) IESE, Universidad de Navarra. Madrid, Spain M.Sc. Mathematical Statistics Universidad Complutense, Institute of Statistics and Operations Research. Madrid, Spain Licenciado en Exactas Universidad Complutense, Faculty of Sciences. Madrid, Spain Dr. Camilo Porta Department of Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy Camillo Porta is a Senior Staff Member of the Unit of Medical Oncology at the IRCCS San Matteo University Hospital Foundation in Pavia, Italy, and an Adjunct Professor of Medical Oncology at the School of Biotechnology and the Postgraduate School of Medical Oncology at the University of Pavia. His clinical interests include clinical trials in advanced kidney cancer and hepatocellular carcinoma, and the development of new targeted agents. He has actively participated in most of the registrative trials of new molecularly targeted agents in kidney cancer.

26 Dr. Tom Powles Clinical Professor of Genitourinary Oncology (HCC), Barts Cancer Institute, London, UK Prof Powles is the lead for solid tumors at Barts Cancer institute. He leads a translational oncology group and is the chief investigator for 10 national and international studies. He has written over 100 publications in the fiend of GU cancer and is on the faculty of a number of international meetings including ESMO GU ASCO and ASCO in Dr. Javier Puente Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Madrid I am a medical oncologist with special interest and expertise in treating patients who have lung and urinary cancers, particularly those with renal cancer. My research focus is studying new agents to treat advanced disease and evaluating novel agents in combined-modality therapy to treat advanced disease. Completed my residency in internal medicine/medical oncology at San Carlos Medical Center (Madrid, Spain). I completed a fellowship in Advanced studies graduate [DEA] & Doctoral credits in the Internal Medicine-Medical Oncology Program, Complutense University of Medicine, Madrid (Spain) between , also Doctoral Thesis and PhD degree (Prognostic factors in recurrent breast cancer patients), Complutense University of Medicine, Madrid (Spain) in In 2006, I joined San Carlos Universitary Hospital s Oncology Service. I am an attending physician and Associated Professor of Medicine Department in Complutense University, Madrid (Spain). I am a member of the committees of the national clinical research groups SOGUG (Spanish Oncologic Genitourinary Group), GECP (Spanish Lung Cancer Group) and GETHI. I ve participated in multiples articles and presentations in national and international meetings, book chapters focused in oncology. Prinicipal and sub-investigator in several clinical trials in lung and genitourinary tumors.

27 Dr. Alfredo Ramos Servicio de Oncología Radioterápica, Hospital Universitario Ramón y Cajal, Madrid - Especialista en Oncología Radioterápica. - Doctor en Medicina y Cirugía. - Profesor Asociado Ciencias de la Salud, Radiología y Física Médica. - Médico Adjunto del Hospital Gregorio Marañón - Jefe de Sección del Hospital del 12 Octubre. - Jefe de Servicio del Hospital Ramón y Cajal. - Autor de numerosos artículos científicos y capítulos de libros de la especialidad. - Participación como Investigador Principal en múltiples ensayos clínicos multicéntricos nacionales e internacionales. - Ponente en Reuniones, Congresos. - Director de Tesis Doctorales. - Miembro de las Sociedades Científicas Oncológicas nacionales y Europeas. - Presidente de la Sociedad Española de Oncología Radioterápica. - Organizador y Coordinador de numerosas Reuniones científicas Nacionales e Internacionales. Dr. Juan Francisco Rodríguez-Moreno Servicio de Oncología Médica, Hospital de Madrid Norte Sanchinarro-CIOCC, Madrid Dr Rodriguez is medical oncologist in the Department of Genitourinary & Gynecological tumors and Coordinator of the Department of Skin Cancer of the Centro Integral Oncológico Clara Campal (Comprehensive Cancer Center). Madrid (Spain). He participates as Clinical collaborator in the Prostate Cancer and Genitourinary Tumours Clinical Research Unit of the Spanish National Cancer Research Center (CNIO). Dr Rodirguez is also Associate Professor at the University CEU San Pablo and member of the Teaching Committee of SOGUG.

28 Dr. Jonathan Rosenberg Associate Physician and Section Head, Memorial Sloan-Kettering Cancer Center, New York, USA Jonathan E. Rosenberg, M.D is an Associate Attending at Memorial Sloan-Kettering Cancer Center, and the Section Head for Non-Prostate Genitourinary Malignancies. He previously was on faculty at UCSF and Dana-Farber. His work focuses on correlating novel genomic findings with clinical outcomes in bladder cancer, as well as developing and testing novel treatment strategies in bladder cancer. Dr. Rosenberg is the Vice Chairman of the Alliance for Clinical Trials In Oncology (formerly CALGB) Genitourinary Committee in charge of the bladder cancer clinical research portfolio. Dr. Rosenberg received his BS from Duke University and his MD from Harvard Medical School. Dr. José Rubio Servicio de Urología, Instituto Valenciano de Oncología (IVO), Valencia Licenciatura y Doctorado en Medicina y Cirugía por la Universidad de Valencia. Formado en Urología vía MIR en la Fundación Puigvert de Barcelona. Fellowship en Biología Molecular en cáncer de próstata en la Universidad de Newcastle. Fellowship en Cirugía Laparoscópica Urológica en el Institute Mutualiste Montsouri de París. Jefe Clínico del Servicio de Urología del Instituto Valenciano de Oncología, en donde trabaja desde Director de la Clínica de Urología y Andrología Dr. Rubio.

29 Dr. Charles Ryan Urologic Oncology Practice, UCSF Medical Center, San Francisco, USA Bachelors degree in Philosophy, Marquette University MD from the University of Wisconsin Medical School. Trained in Internal Medicine at the University of Wisconsin and Medical Oncology at Memorial Sloan Kettering Cancer Center. Current title Associate Professor of Medicine and Urology and Program Leader, Genitourinary Medical Oncology at the Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco. Dr. Eric Small Urologic Cancer Service and Urologic Oncology Research, UCSF Medical Center, San Francisco, USA Eric Small is currently Professor of Medicine and Urology at the University of California, San Francisco. Dr. Small serves as Chief of the Division of Hematology and Oncology, as well as Deputy Director of the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests have been in the treatment of advanced prostate cancer, and in particular in immunotherapy, and therapeutics targeted at the Androgen Receptor. Dr. Small was involved in the early work that let to the approval of Sipuleucel T, Abiraterone, and Ipilimumab. He has served as Associate Editor for GU Oncology for the Journal of Clinical Oncology (JCO), and as Chair of the CALGB/Alliance GU Committee. He is the PI of a Stand Up to Cancer/Prostate Cancer Foundation/ AACR Dream Team studying mechanisms of resistance in patients with advanced prostate cancer.

30 Dra. Roser Torra Servicio de Nefrología, Fundació Puigvert, Barcelona Roser Torra, MD, PhD, is a consultant in the Nephrology Department of Fundació Puigvert in Barcelona. Since 1994 she has been involved in clinical practice, research and clinical trials on various genetic renal diseases such as ADPKD, Fabry disease, Alport syndrome, ARPKD, TSC, and FSGS. She is coordinator of the working group on hereditary kidney disease within the Spanish Society of Nephrology and Chairman of the Scientific Committee of AIRG-E. Dr. Francisco Zambrana Servicio de Oncología Médica, Hospital Universitario Infanta Sofía, Madrid University of Seville Medical School. Clinical Fellowship in Medical Oncology (Hospital Universitario Virgen Macarena, Seville. 2009). MPhil in tumor pathology (University of Seville, 2006). Observership program at MD Anderson Cancer Center (Breast and Lymphoma Departments, 2008) and University Hospital (Palliative Medicine, University of Navarra, 2006). MPhil in Oncology Research (Universidad San Pablo CEU & CIOCC, 2012). Ongoing clinical research in metabolomics (volatile organic compounds) and genomics for prediction of response to chemoradiation. Areas of interest: GU, lung and head & neck Oncology.

31 IV SIMPOSIO CIENTÍFICO SOGUG

32 SEDE VENUE Casino de Madrid Alcalá, 15, Madrid - T *Para acceder a la sede del Simposio es imprescindible el uso de chaqueta y corbata Jacket and tie are required to enter the meeting venue Idioma principal: inglés Disponible traducción simultánea Symposium s main language: English Simultaneous translation also provided Organizado por / Organized by Patrocinadores Principales / Main Sponsors Patrocinadores / Sponsors Colaboradores / Collaborators Con el auspicio de / Under auspices of 16, CAT 1 ESMO-MORA POINTS Actividad acreditada por la Comisión de Formación Continuada de las Profesiones Sanitarias de la Comunidad de Madrid con 2,2 créditos / Activity accredited by the Spanish System of Continuing Medical Education with 2,2 points Technical Secretariat TACTICS MD - T info@tacticsmd.net